健脾利湿解毒方治疗慢性结肠炎脾虚湿毒证疗效研究  

The clinical effect of Jianpi Lishi Jiedu decoction in treating chronic colitis of spleen deficiency and dampness-toxin syndrome

在线阅读下载全文

作  者:陈晓旭[1] 王光铭[1] 刘万里 吴昊[1] CHEN Xiaoxu;WANG Guangming;LIU Wanli;WU Hao(The Nanjing University of Chinese Medicine Affiliated Nanjing Hospital of Integrated Chinese and Western Medicine,Nanjing 210014,China)

机构地区:[1]南京中医药大学附属南京市中西医结合医院,江苏南京210014 [2]南京医科大学附属南京医院南京市第一医院,江苏南京210006

出  处:《陕西中医》2024年第12期1640-1643,1648,共5页Shaanxi Journal of Traditional Chinese Medicine

基  金:江苏省中医药科技发展计划项目(YB2020030);南京市医学科技发展重点项目(ZKX21057)。

摘  要:目的:观察健脾利湿解毒方治疗慢性结肠炎脾虚湿毒证的临床疗效。方法:选取120例确诊为慢性结肠炎脾虚湿毒证的患者,采取随机数字表法分为观察组以及对照组,每组60例。对照组采取口服复方嗜酸乳杆菌片治疗,观察组在对照组治疗的基础上采取口服健脾利湿解毒方治疗,疗程均为3个月。治疗完成后比较两组治疗前后中医证候积分及脑肠肽[血管活性肠肽(VIP)、5-羟色胺(5-HT)、P物质(SP)、生长抑素(SS)]、炎症因子[C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-17(IL-17)]和粪便钙卫蛋白(FC)水平。比较两组总有效率及不良反应发生情况。结果:治疗后,观察组总有效率高于对照组(P<0.05);治疗后,两组中医证候积分均较治疗前降低,组间相比,观察组水平更低(均P<0.05);治疗后,两组VIP、5-HT、SP、SS、CRP、TNF-α、IL-17水平以及FC水平较治疗前降低,组间相比,观察组水平更低(均P<0.05)。两组均无不良反应。结论:健脾利湿解毒方可改善慢性结肠炎患者各项症状,抑制脑肠肽水平及炎性反应,且临床安全性高、无明显不良反应。Objective:To observe the clinical effect of Jianpi Lishi Jiedu decoction in treating chronic colitis of dampness-toxin syndrome due to spleen deficiency.Methods:A total of 120 patients with spleen deficiency and dampness-toxicity syndrome of chronic colitis were selected,they were randomly divided into observation group and control group with 60 patients in each group.The control group was treated with compound Lactobacillus acidophilus tablet,and the observation group was treated with Jianpi Lishi Jiedu decoction on the basis of the treatment in the control group.The course of treatment was three months.After treatment,the TCM syndrome scores and the levels of brain-gut peptide[vasoactive intestinal peptide(VIP),5-hydroxytryptamine(5-HT),substance P(SP),somatostatin(SS)],inflammatory factors[C-reactive protein(CRP),tumor necrosis factor(TNF-α),interleukin-17(IL-17)]and fecal calprotectin(FC)were compared between the two groups.The total effective rate and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate of observation group was higher than that of control group(P<0.05).After treatment,TCM syndrome scores of both groups were lower than before treatment,and the level of observation group was lower than control group(all P<0.05).After treatment,the levels of VIP,5-HT,SP,SS,CRP,TNF-α,IL-17 and FC in two groups were lower than before treatment,and the levels in observation group were lower than control group(all P<0.05).There were no adverse reactions in both groups.Conclusion:It can improve the symptoms of patients with chronic colitis,inhibit the level of brain-gut peptide and inflammatory response,and has high clinical safety and no obvious adverse reactions.

关 键 词:慢性结肠炎 脾虚湿毒证 健脾利湿解毒方 脑肠肽 炎症因子 粪便钙卫蛋白 

分 类 号:R574.62[医药卫生—消化系统]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象